Rep. Bruce Westerman Sells Off Shares of Edwards Lifesciences Co. (NYSE:EW)

Representative Bruce Westerman (R-Arkansas) recently sold shares of Edwards Lifesciences Co. NYSE: EW. In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Edwards Lifesciences stock on April 21st. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of UniCredit OTCMKTS: UNCRY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Siemens Aktiengesellschaft OTCMKTS: SIEGY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of GSK NYSE: GSK on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 4/21/2025.
• Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 4/21/2025.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Chevron NYSE: CVX on 4/21/2025.

Edwards Lifesciences Stock Performance

NYSE EW opened at $75.48 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The business has a 50 day simple moving average of $71.59 and a two-hundred day simple moving average of $71.58. The stock has a market capitalization of $44.28 billion, a PE ratio of 10.83, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $0.66 earnings per share. On average, research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $26,000. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the first quarter valued at approximately $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $27,000. SouthState Corp purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $27,000. Finally, Millstone Evans Group LLC bought a new position in Edwards Lifesciences in the fourth quarter worth approximately $29,000. Institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at $3,555,402. This represents a 12.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Friday, May 9th. The stock was sold at an average price of $74.40, for a total transaction of $837,000.00. Following the completion of the transaction, the chief financial officer now directly owns 41,098 shares in the company, valued at $3,057,691.20. This represents a 21.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,681 shares of company stock worth $6,492,703 over the last 90 days. Company insiders own 1.29% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the topic of several recent research reports. StockNews.com upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday, April 25th. Piper Sandler raised their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday. Truist Financial cut their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, Evercore ISI decreased their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $79.60.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.